ORV 116E cost effective for prevention of rotavirus in India

Abstract

A dynamic simulation model of rotavirus transmission was used to evaluate the cost effectiveness and public health impact of universal vaccination with the 116E vaccine at 6, 10 and 14 weeks of age in infants in India, compared with no rotavirus vaccination, from an all-payer (public sector and family) perspective and a societal perspective over a 30-year time horizon. Compared with no vaccination, full implementation of the 116E vaccination programme was predicted to avert 0.0404 disability-adjusted life-years (Dalys) per infant at a cost of INR138,· resulting in an estimated incremental cost-effectiveness ratio (ICER) of INR3429 per DALY averted from an all-payer perspective, which was well below the WHO willingness-to-pay threshold.